Close

BioMarin Pharmaceuticals (BMRN) Misses Q4 EPS by 12c; Guides FY12 Revs Below

February 16, 2012 4:01 PM EST
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $115.3 million.

Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.

For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings